Delving into the Latest Updates on Parecoxib Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide, Parecoxib sodium (USAN), Rayzon

+ [8]

Target

COX-2

Mechanism

COX-2 inhibitors(Cyclooxygenase-2 inhibitors)

Therapeutic Areas

Nervous System Diseases

Active Indication

Pain, Postoperative

Inactive Indication

ColicRenal Colic

Originator Organization

Pfizer Inc.

Active Organization

Pfizer Europe MA EEIG

Inactive Organization

Pfizer Inc.

Drug Highest PhaseApproved

First Approval Date

EU (22 Mar 2002),

Pain, Postoperative

RegulationPriority Review (CN)

Login to view timeline

Structure

Molecular FormulaC19H18N2O4S

InChIKeyTZRHLKRLEZJVIJ-UHFFFAOYSA-N

CAS Registry198470-84-7

View All Structures (2)

Because of the important role of inflammation in the pathophysiology of SAH, it was hypothesized that its pharmacological manipulation might improve the prognosis of patients. In recent years, the effects of several groups of anti-inflammatory drugs on the development of complications after SAH have been described. Initially promising, glucocorticoids, thought to reduce cerebrovascular inflammation, brain swelling, and headache, failed in clinical trials. Studies have not provided clear evidence of the beneficial effects of these drugs in patients after SAH. Therefore, the administration of glucocorticoids is not currently part of the recommended practice. In addition, glucocorticoid treatment is associated with adverse effects that worsen outcomes, including hyperglycemia, infection, and the risk of gastrointestinal bleeding.

Start Date01 Jan 2025

Sponsor / Collaborator

St. Anne's University Hospital Brno

[+1]

NCT06623513 / Not yet recruitingPhase 2IIT

A Single-Center, Prospective, Randomized, Controlled, Exploratory Trial Comparing the Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis: The PRECISE Trail

This study aims to evaluate the efficacy and safety of parecoxib versus indomethacin in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). It is a single-center, prospective, randomized, controlled, exploratory trial. Participants will be randomly assigned to receive either parecoxib or indomethacin as a preventive treatment. The primary endpoint is to compare the efficacy of the two drugs in reducing the incidence of PEP. Secondary endpoints include the incidence of moderate to severe PEP and post-ERCP-related adverse events. This study will systematically assess the efficacy and safety of both drugs, providing preliminary data for future larger confirmatory trials.

Start Date01 Oct 2024

Sponsor / Collaborator

Shanghai First People's Hospital

NCT06600282 / Not yet recruitingPhase 4

A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Parecoxib After Intravenous Bolus of Parecoxib in Healthy Volunteers Under Fasting Conditions

A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of parecoxib after intravenous bolus of parecoxib in healthy volunteers under fasting conditions

Start Date01 Oct 2024

Sponsor / Collaborator

Yung Shin Pharm Ind Kunshan Co. Ltd.

100 Clinical Results associated with Parecoxib Sodium

Login to view more data

100 Translational Medicine associated with Parecoxib Sodium

Login to view more data

100 Patents (Medical) associated with Parecoxib Sodium

Login to view more data

688

Literatures (Medical) associated with Parecoxib Sodium

31 Dec 2024·International Journal of Hyperthermia

Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy

Article

Author: Chang, Sheng-Chi ; Yeh, Hung-Chieh ; Ho, Chien-Lin ; Cheng, Chih-Chung ; Su, Pei-Wen

PURPOSECisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney disease (CKD) is scarce and less investigated. This study aims to investigate the incidence of CKD following cisplatin-based HIPEC and to analyse the associated risk factors.MATERIALS AND METHODSFrom January 2016 to August 2021, a total of 55 patients treated with CRS and cisplatin-based HIPEC for peritoneal carcinomatosis were categorized retrospectively into groups, with and without CKD. Demographics, comorbidity, surgery, postoperative management, and complications were collected to evaluate risk factors for cisplatin-based HIPEC-related CKD. Univariate and multivariate analyses were conducted to confirm the correlation between different variables and CKD occurrence.RESULTSOf the 55 patients, 24 (43.6%) patients developed AKI and 17 (70.8%) patients of these AKI patients progressed to CKD. Multivariate regression analysis identified intraoperative use of parecoxib (Odds Ratio (OR) = 4.39) and intraoperative maximum temperature > 38.5°C (OR = 6.40) as major risk factors for cisplatin-based HIPEC-related CKD occurrence. Though type II diabetes mellitus and intraoperative complications were the independent risk factors of AKI following cisplatin-based HIPEC, but they were not shown in CKD analysis.CONCLUSIONIntraoperative use of parecoxib during cisplatin-based HIPEC emerged as a significant risk factor for postoperative CKD. Clinicians should exercise caution in prescribing parecoxib during HIPEC procedures. Additionally, maintaining intraoperative body temperature below 38.5°C might be crucial to mitigate the risk of CKD development. This study underscores the importance of identifying and preventing specific risk factors to improve long-term renal outcomes in patients undergoing cisplatin-based HIPEC.

01 Dec 2024·Neuropharmacology

Increased levels of Escherichia-Shigella and Klebsiella in the gut contribute to the responsivity of placebo analgesia

Article

Author: Hu, Suwan ; Yang, Chun ; Liu, Cunming ; Wang, Di ; Yang, Siqi ; Wu, Zifeng ; Bu, Yuchen ; Zhang, Qi ; Zhang, Xinying ; Huang, Chaoli ; Wang, Yuanyuan

Placebo analgesia is observed in both humans and animals. Given the complexity of placebo analgesia involving a variety of neurobiological, psychological, and psychosocial processes, further investigation into its underlying mechanisms is essential. Gut microbiota has been implicated in the responsivity of placebo analgesia, but its precise role remains unknown and warrants further investigations. Here, we conducted a conditioning training model with chronic inflammatory pain induced by complete Freund's adjuvant (CFA) in mice, associating parecoxib with different cues. Hierarchical clustering analysis of placebo analgesia behaviors was employed to classify mice into responders and non-responders phenotypes. Approximately 40% of CFA mice undergoing conditioning training exhibited placebo analgesia. Notably, placebo analgesia responders displayed reduced anxiety-like behaviors. 16S rRNA results revealed a distinct composition of gut microbiota composition among the control, placebo analgesia non-responders and responders groups. Notably, levels of Escherichia Shigella and Klebsiella in the gut were increased considerably in the placebo analgesia responders as compared to both control and non-responders groups. In conclusion, placebo analgesia responders demonstrated marked analgesia, reduced anxiety-like behaviors, and increased levels of Escherichia-Shigella and Klebsiella, implying a potential linkage between gut microbiota and placebo analgesia.

01 Nov 2024·Pflügers Archiv - European Journal of Physiology

Immune-mediated impairment of tonic immobility defensive behavior in an experimental model of colonic inflammation

Article

Author: Brentegani, Mariulza Rocha ; Menescal-de-Oliveira, Leda ; Saia, Rafael Simone ; Giusti, Humberto ; Teixeira, Fernanda Pincelli

Ulcerative colitis has been associated with psychological distress and an aberrant immune response. The immunomodulatory role of systemic cytokines produced during experimental intestinal inflammation in tonic immobility (TI) defensive behavior remains unknown. The present study characterized the TI defensive behavior of guinea pigs subjected to colitis induction at the acute stage and after recovery from intestinal mucosa injury. Moreover, we investigated whether inflammatory mediators (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-8, IL-10, and prostaglandins) act on the mesencephalic nucleus, periaqueductal gray matter (PAG). Colitis was induced in guinea pigs by intrarectal administration of acetic acid. The TI defensive behavior, histology, cytokine production, and expression of c-FOS, IBA-1, and cyclooxygenase (COX)-2 in PAG were evaluated. Colitis reduced the duration of TI episodes from the first day, persisting throughout the 7-day experimental period. Neuronal c-FOS immunoreactivity was augmented in both columns of the PAG (ventrolateral (vlPAG) and dorsal), but there were no changes in IBA-1 expression. Dexamethasone, infliximab, and parecoxib treatments increased the duration of TI episodes, suggesting a modulatory role of peripheral inflammatory mediators in this behavior. Immunoneutralization of TNF-α, IL-1β, and IL-8 in the vlPAG reversed all effects produced by colitis. In contrast, IL-10 neutralization further reduced the duration of TI episodes. Our results reveal that peripherally produced inflammatory mediators during colitis may modulate neuronal functioning in mesencephalic structures such as vlPAG.

100 Deals associated with Parecoxib Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03717	Parecoxib Sodium	M01AH04	DB08439

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pain, Postoperative	NO	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	IS	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	EU	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	LI	Pfizer Europe MA EEIG	22 Mar 2002

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain	Phase 1	AU	Pfizer Inc.	01 Apr 2003
Colic	Phase 1	IT	Pfizer Inc.	01 Apr 2002
Renal Colic	Phase 1	IT	Pfizer Inc.	01 Apr 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ILCA2020	Not Applicable	Hepatocellular Carcinoma	-	Parecoxib sodium + TAP block	qhprfowhmb(khklptfqlw) = No significant differences were found between the two groups related to adverse events gnzbakhfgz (pxmjajuwmz ) View more	Positive	13 Sep 2020
ILCA2020	Phase 3	Hepatocellular Carcinoma	80	Parecoxib sodium 40 mg	posbvqfzrq(jzqhbutzic) = tozutahvve mnuxdylkmb (fmgyyrzusk, 9.8 - 28.2) View more	Positive	13 Sep 2020
				Placebo	posbvqfzrq(jzqhbutzic) = gzuuhdcozo mnuxdylkmb (fmgyyrzusk, 8.1 - 19.9) View more
NCT03059238 (ASCO_GI2020)	Phase 3	Hepatocellular Carcinoma	213	Celecoxib	(bbfwujapgu) = wdhqjiycle eueojkdili (nzgybvqmxc )	Positive	04 Feb 2020
				Parecoxib	(bbfwujapgu) = ftgmxeturd eueojkdili (nzgybvqmxc )
Pubmed \| Anesth Analg	Not Applicable	-	620	Parecoxib	yezheeqsii(zrceylclnr) = uzpzwjixwf szikmyudud (bcqrwhxyjz, 0.33 - 0.96)	Positive	01 Jun 2017
				Placebo	yezheeqsii(zrceylclnr) = rsdzkrvsso szikmyudud (bcqrwhxyjz )
NCT01566669 (PCEA, Pubmed \| J Biol Chem)	Not Applicable	-	240	Parecoxib	epjbgiutce(fmkyyvlzft) = pqudmsoapq ohqloinwoh (obtkosmnht ) View more	Positive	01 Jan 2016
				Placebo	epjbgiutce(fmkyyvlzft) = tsdfvasfnj ohqloinwoh (obtkosmnht ) View more
NCT00346268 (PROSTATECTOMY, Pubmed \| BMC Anesthesiol) Manual	Phase 4	Hemorrhage \| Analgesia	105	Morphine+parecoxib	thrxnvkoix(npmqulozte) = qrbpktspln hxsadhltmh (uymznujsyd, 24.1) View more	Positive	09 Mar 2015
				Morphine+Placebo	thrxnvkoix(npmqulozte) = wtjaupvkij hxsadhltmh (uymznujsyd, 28) View more
NCT00553605 (NAP, CTgov)	Phase 4	Renal Colic	340	Parecoxib (Parecoxib)	ibyygmwirn(adflcmnxrf) = afyhbupkmo cicjjmwvai (txcgaitcpp, rkncqmyfyn - mhmdouiabe) View more	-	28 Jan 2013
				Ketoprofen (Ketoprofen)	ibyygmwirn(adflcmnxrf) = whcelyvfhh cicjjmwvai (txcgaitcpp, avwjznfqwj - xhgdabbehq) View more
NCT00346268 (PROSTATECTOMY, CTgov)	Phase 4	Pain, Postoperative	105	Parecoxib+Morphine (Parecoxib and Morphine)	fjplzxuzhv(aecduoynua) = godnyspwtx zlhnhxearz (lrhhphpqbz, opcqxmhvtu - vdjbqprymv) View more	-	28 Oct 2011
				Placebo+Morphine (Placebo and Morphine)	fjplzxuzhv(aecduoynua) = ccfsqcomfz zlhnhxearz (lrhhphpqbz, gpiuibwdfz - iutgockwsj) View more
NCT00455117 (Pubmed \| Vet Anaesth Analg)	Phase 4	Pain	-	Parecoxib 40 mg	(qktvewrkct) = jollyuqerv rbghruwnnf (zedkahmoqg )	Negative	01 Sep 2011
				Placebo	(qktvewrkct) = pvxezyvjqa rbghruwnnf (zedkahmoqg )